The Lead Episode 155: A Discussion of A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation versus Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent Atrial Fibrillation (AVANT GUARD)-The Lead Episode 155 Bonus Video File

Video Transcription

Video Summary

The transcript summarizes the ADVANTGARDE trial, an international randomized study of 440 patients with de novo persistent atrial fibrillation. Patients were assigned to first-line pulse field ablation (PFA) with pulmonary vein and posterior wall isolation, or to antiarrhythmic drug therapy. At 12 months, PFA showed better rhythm control, with 56% freedom from recurrent AF/flutter versus 31% with drugs, and implantable loop recorders showed very low AF burden in the ablation arm.  <br /><br />The panel emphasized that the trial is notable for testing ablation as initial therapy in persistent AF, a population traditionally treated with drugs first. However, an early safety pause occurred after six neurologic embolic events in the PFA arm; the protocol was revised to exclude higher-risk patients, after which no further embolic events were seen. The speakers concluded that PFA may become a first-line option, while questions remain about posterior wall isolation and long-term safety.

Keywords

ADVANTGARDE trial

persistent atrial fibrillation

pulse field ablation

pulmonary vein isolation

antiarrhythmic drug therapy

posterior wall isolation